Clinical Trials Directory

Trials / Completed

CompletedNCT01727973

Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy

Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Sun Yat-sen University · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 wk, for patients with active moderate-severe Graves' Orbitopathy (GO).

Detailed description

Graves'orbitopathy is an autoimmune disease characterised by an inflammatory phase followed by fibrosis. Surgery to correct eyelid swelling, proptosis, and diplopia is effective, but can not be done until the inflammatory phase has passed. To arrest the inflammatory phase, several types of immunosuppressive treatments have been investigated. Corticosteroids are the first-choice immunosuppressive treatment, but they often cause severe side-effects. Subantimicrobial dose doxycycline posses known anti-inflammatory effects that are separate from their antibacterial mode of action. This mode of action has lead to the routine use of subantimicrobial dose doxycycline for rosacea, periodontitis and multiple sclerosis. We propose to test the effect of subantimicrobial dose doxycycline for non-sight threatening, moderate-severe, inflammatory GO.

Conditions

Interventions

TypeNameDescription
DRUGDoxycyclineTab. Doxycycline 50 mg PO per day for 12 weeks

Timeline

Start date
2012-10-01
Primary completion
2013-11-01
Completion
2013-11-01
First posted
2012-11-16
Last updated
2013-12-10

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01727973. Inclusion in this directory is not an endorsement.